After years of pressure from prevention advocates, FDA has finally given the other rubber a new name - the internal condom – and a new classification.
After years of anecdotes and speculation, harm reduction and pharma watchdog advocates have data to back claims that the spike in opioid deaths in the U.S. can be tied to pharmaceutical companies marketing highly addictive opioids to doctors.
Our series on mentor-mentee researchers continues with Ellen Eaton, M.D., and Kelsie Dodson, with the University of Alabama at Birmingham.
High HIV prevalence among black MSM on PrEP; substance use reduction lessens depressive symptoms; correlations between pain symptoms and age; the impact of seroconversion and antiretroviral therapy on risk behaviors.
PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.
With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
A dial-in hotline program in New York City has helped qualified patients access post-exposure prophylaxis (PEP) at their local pharmacies, raising the possibility that remote screening methods could be an important way to bolster PEP use.
A summary of a workshop at the U.S. Conference on AIDS titled "The Consensus: Communicating About HIV Treatment as Prevention (TasP)."
Three experts share their perspectives on treatment as prevention (TasP) at the U.S. Conference on AIDS.
What do on-demand PrEP advances seen in men mean for a developing a biomedical prevention agenda for women?